Pharmaceutical developer NewBiotics Inc. of San Diego, Calif., has named H. Michael Shepard, PhD, as company president.
Shepard was chief scientific officer and vice president of research at Canji, Inc. before taking the position. He helped develop the p53 gene product for cancer therapy and worked with management to secure financing for the company.
NewBiotics is privately held and is primarily researching breakthrough drugs to treat cancer and infectious disease.
Shepard was a Damon Runyon Fellow at Indiana University and received his doctorate in molecular, cellular, and developmental biology.
